Ligence enrolls in one of the largest Stress Echocardiography studies

We are excited and proud to be working with leading minds in echocardiography to define the future of heart imaging. Ligence is participating in one of the largest echocardiography studies Stress Echo 2030 (SE2030)!

The study aims to recruit ≥10 000 patients in the next 5 years (2021-2025) followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time and in any patient.

You are welcome to read the first publication from this study here:

https://www.mdpi.com/2077-0383/10/16/3641

Share the Post:

Related Posts

Ligence, a leader in echocardiography automation technology, has attracted €3 million in seed funding led by venture capital firm Simpact Ventures. This funding will drive Ligence’s expansion efforts as the